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ABSTRACT
Checkpoint blockade has demonstrated promising antitumor responses in approximately 10–40% of
patients. However, the majority of patients do not make a productive immune response to their tumors
and do not respond to checkpoint blockade. These patients may beneﬁt from an effective vaccine that
stimulates high-avidity T cell responses in combination with checkpoint blockade. We have previously
shown that incorporating TRP-2 and gp100 epitopes into the CDR regions of a human IgG1 DNA
(ImmunoBody: IB) results in signiﬁcant tumor regression both in animal models and patients. This
vaccination strategy is superior to others as it targets antigen to antigen-presenting cells and stimulates
high-avidity T cell responses. To broaden the application of this vaccination strategy, 16 NY-ESO-1
epitopes, covering over 80% of HLA phenotypes, were incorporated into the IB (SCIB2). They produced
higher frequency and avidity T cell responses than peptide vaccination. These T cells were of sufﬁcient
avidity to kill NY-ESO-1-expressing tumor cells, and in vivo controlled the growth of established B16-NY-
ESO-1 tumors, resulting in long-term survival (35%). When SCIB2 was given in combination with Treg
depletion, CTLA-4 blockade or PD-1 blockade, long-term survival from established tumors was signiﬁcantly
enhanced to 56, 67 and 100%, respectively. Translating these responses into the clinic by using a
combination of SCIB2 vaccination and checkpoint blockade can only further improve clinical responses.
Abbreviations: Ab, antibody; APC, antigen-presenting cells; CDR, complementary determining region; CTLA-4, cyto-
toxic T lymphocyte associated protein-4; ELISA, enzyme-linked immunosorbent assay; Elispot, enzyme-linked immu-
nospot; EP, electroporation; FBS, fetal bovine serum; FcR, Fc receptor; IFA/CFA, Incomplete/complete Freund’s
adjuvant; PBMCs, peripheral blood mononuclear cells; PD-1, programmed cell death protein 1; PD-L1, programmed
death ligand 1; PI, proliferation index; Treg, regulatory T cells
KEYWORDS
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Introduction
Checkpoint inhibitors have reformed cancer treatments of mel-
anoma, with 20–30% of patients responding to ipilimumab
(CTLA-4 blockade) and to PD1/PD-L1 blockade.1,2 More
recently, among previously untreated patients with metastatic
melanoma, anti-PD-1 alone or combined with anti-CTLA-4
resulted in signiﬁcantly longer progression-free survival than
anti-CTLA-4 alone.3 Although the responses are promising,
not all melanoma patients respond and the responses in other
cancers have not been as high. Recent studies show that the
response to checkpoint blockade may be related to the fre-
quency of neo-epitopes that stimulate new T cell responses that
have not been tolerized.4,5 However, the majority of patients
are non-responders and do not have the appropriate mutations,
so they fail to stimulate a productive immune response. These
patients may beneﬁt from an effective vaccine that stimulates
high-avidity CD4C and CD8C responses in combination with
checkpoint blockade. This is not a new concept as the initial tri-
als with ipilimumab used gp100 peptide vaccination. However,
the problem with peptide vaccinations is that they do not gen-
erate T cells with sufﬁcient avidity to clear the tumor.6
Due to its restricted normal expression and widespread
tumor expression (including esophageal, lung, liver, ovarian,
melanoma, bladder, prostate and breast cancer),7-9 NY-ESO-1
is an ideal target for a tumor therapy. Indeed, T cell responses
restricted through multiple HLA alleles have been reported,10-12
allowing a cancer vaccine that targets this antigen to be applica-
ble to both a broad range of patients with different HLA types
and also to a wide range of tumors. A variety of vaccination
approaches have been tried with NY-ESO-1, including adminis-
tration of synthetic peptide, recombinant protein and DNA
encoding full-length NY-ESO-113-15 but they have failed to con-
trol tumor growth.13,16,17 This may be related to induction of
low-avidity T cell responses with restricted ability to recognize
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tumor cells and the profoundly immunosuppressive tumor
environment which further restricts T cell activity.
We have previously shown that a DNA plasmid encoding T cell
epitopes within the complementary determining regions (CDR)18
of a human IgG1 antibody (ImmunoBody) stimulates high-avid-
ity T cell responses.19 Electroporation (EP) increases DNA uptake
over 1,000-fold and has an adjuvant effect resulting from local tis-
sue damage and the subsequent expression of pro-inﬂammatory
cytokines.20,21 The ImmunoBody acts by direct presentation of
the DNA within antigen-presenting cells and cross-presentation of
secreted protein via the high-afﬁnity FcgR1 receptor (CD64).
When comparing DNA and protein immunization of
ImmunoBody, the DNA gave higher frequency and avidity
responses suggesting direct presentation of the DNA within anti-
gen-presenting cells. However, experiments in CD64-knockout
mice but not CD32-knockout mice induced lower frequency and
avidity T responses in wild-type mice suggesting that cross-presen-
tation of secreted protein via the high-afﬁnity FcgR1 receptor
(CD64) was important. Although either presentation induces T
cell responses, it is only the combination that induces T cells with
sufﬁciently high avidity to kill tumor cells.18,19 This was further val-
idated by comparison of the same ImmunoBody DNA express-
ing Fab or whole antibody molecules, which showed much weaker
responses in the absence of Fc. We have also replaced human IgG1
from the same DNA backbone vector with moIgG2a; both huIgG1
and moIgG2a can stimulate immune responses in mice.17 SCIB1 is
an ImmunoBody encoding a human IgG1 antibody, with three
epitopes from gp100 and one from TRP-2 engineered into its CDR
regions, which has entered clinical trials. A clinical study in stage
III/IV melanoma patients with tumor present at study entry
showed that SCIB1 could induce T cell responses in 10/11 patients
with no associated toxicity. Overall survival was 19 mo with
patients showing clinical responses including two partial responses
and stable disease. Results were even more dramatic in patients
with fully resected disease as they all showed a T cell response and
are still alive with a current median observation time of 3 y. Two-
and three-year recurrence-free survival for stage III resected
patients was 89 and 67%, respectively, and for stage IV resected
patients, it was 71% at both time points.22
In this study, we report the validation of SCIB2 which enco-
des NY-ESO-1 T cell epitopes in the CDR regions of the human
IgG1 vector. This approach stimulates higher avidity T cell
responses than peptide and demonstrates the advantage of
combining both high-avidity T cell responses with checkpoint
blockade. The combination of SCIB2 with PD1 blockade led to
complete tumor regression.
Results
Melanoma patients demonstrate NY-ESO-1-speciﬁc T cell
responses
Previous studies suggest NY-ESO-1-speciﬁc T cell responses
could be detected in peripheral blood mononuclear cells
(PBMCs) from cancer patients.23 We selected 16 epitopes from
NY-ESO-1 covering the most common class I and class II hap-
lotypes and conﬁrmed that melanoma patients show T cell
responses to these peptides. 10 of 11 (90%) patients responded
to one or more of the CD8C epitopes (Fig. 1A) and 9 of 11
(82%) to one or more of the CD4C epitopes (Fig. 1B). The clini-
copathology and HLA types are shown in Table S1. This data
suggested that inclusion of these epitopes within SCIB2 would
provide a vaccine that could target the majority of HLA types.
Table 1 summarizes the HLA-restricted NY-ESO-1 epitopes
that have been incorporated into SCIB2.
Immunization with SCIB2 generates strong NY-ESO-1-
speciﬁc CD8C and CD4C responses in HLA transgenic mice
HHDII (HLA-A0201) transgenic mice immunized with SCIB2
showed high-frequency responses to the CD8C T cell epitope
NY-ESO-1 157–165, and the CD4C T cell epitopes 87–111 and
119–143 over background control (Fig. 2A) conﬁrmed by in
vitro CD8C and CD4C depletion, respectively (Figs. S1A and
B). In this instance, the CD4C-mediated responses were I-Ab
restricted (Fig. S1B).
To assess the immune response in a mouse with only human
MHC, we immunized HHDII/DR1 mice that have human class
I HLA0201 and human class II (HLA-DR1) and no mouse
MHC. As illustrated in Fig. 2B, T cells from immunized HHDII/
DR1 mice show signiﬁcantly higher epitope-speciﬁc responses to
NY-ESO-1 157–165 over background control. This is consistent
Figure 1. Peripheral blood lymphocytes (PBMC) from melanoma patients show
spontaneous response to selected NY-ESO-1 peptides. The in vitro proliferation
assay was performed on PBMC from melanoma patients following 10 d incubation
with NY-ESO-1 (A) CD8C peptides (NY-ESO-1 83–91, 88–96, 157–165, 158–166)
and (B) CD4C peptides (NY-ESO-1 87–111 and 119–143).
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with Fig. S1C showing paired response between background con-
trol and NY-ESO-1 157–165. SCIB2-immunized mice also
showed signiﬁcantly higher antigen-speciﬁc responses to 87–111
and 119–143, indicating that the 87–111 and 119–143 sequences
also induce responses restricted through HLA-DR1 (Fig. 2B).
Addition of HLA-DR-blocking Ab into the assay conﬁrmed that
these responses were HLA-DR-restricted CD4C responses
(Fig. S1D). To assess if the DNA vector alone could act as an
adjuvant and generate NY-ESO-1-speciﬁc immune responses,
mice were immunized with vector expressing the human IgG1
antibody with no NY-ESO-1 epitopes inserted. The empty anti-
body vector did not generate any NY-ESO-1-speciﬁc IFNg
responses (Fig. S1E). In addition, no responses to irrelevant pep-
tides were observed in SCIB2-immunized mice (Fig. S1F).
High-avidity T cell (3.8 £ 10¡9, 1.7 £ 10¡8) responses were
demonstrated by titration of the NY-ESO-1 157–165 peptide in
both HHDII and HHDII/DR1 mice (Fig. 2C). These high-avid-
ity T cell responses result in killing of NY-ESO-1-positive
tumor cells (B16/HHDII/NY-ESO-1 cells) but not of HLA-mis-
matched or antigen-negative control cells (Fig. 2D). This data
demonstrated that SCIB2 can be used in vivo to stimulate
strong CD8C T cell responses that are capable of tumor cell
lysis in vitro as well as induction of CD4C T cell responses.
To further assess the cytotoxic potential of the encoded epit-
opes, splenocytes from mice immunized with SCIB2 were incu-
bated with NY-ESO-1 peptides in vitro for 40 h and the
supernatants were analyzed by granzyme B ELISA. All three
epitopes stimulated signiﬁcant amounts of granzyme B includ-
ing the CD4C epitopes NY-ESO-1 87–111 and 119–143 epito-
pes, these responses could be completely blocked by mouse
MHC class II blocking Ab (Fig. 2E).
SCIB2 induces higher avidity CD8C responses than peptide
vaccination
Many clinical trials using NY-ESO-1 vaccines have failed to show
clinical beneﬁts in patients. To determine whether SCIB2was likely
to be more potent, the frequency and avidity of T cell responses
generated from vaccination with SCIB2 and conventional peptide
immunization were compared. SCIB2 immunization stimulated
higher frequency T cell responses speciﬁc for the NY-ESO-1 157–
165 epitope than peptide immunization (SCIB2 vs. peptide
pD 0.0004) (Fig. 3A). The functional avidity, as measured by pep-
tide titration, showed that SCIB2 (9 £ 10¡9 M) generated a 100-
fold higher avidity than peptide (10¡6 M) immunized mice
(Fig. 3B).
Differences in functional avidity have been directly corre-
lated with antitumor activity. NY-ESO-1 157–165-speciﬁc T
cells induced by immunization with either SCIB2 or with pep-
tide were able to speciﬁcally recognize peptide pulsed tumor
targets; however, SCIB2 immunization was the only approach
which showed recognition and lysis of naturally processed and
presented NY-ESO-1 antigen on tumor cells (Fig. 3C). Overall,
this demonstrated that NY-ESO-1 157–165-speciﬁc T cells gen-
erated from mice immunized with SCIB2 were more efﬁcient at
targeting tumor cells in vitro.
Immunization with SCIB2 generates strong antitumor
immunity
To see if the enhanced in vitro recognition of tumor targets was
also reﬂected in vivo, mice with established B16/HHDII/NY-
ESO-1 tumors were immunized with SCIB2. Mice immunized
with SCIB2 demonstrate a signiﬁcant delay in tumor growth
(p < 0.05) (Figs. 4A, B and C) and 35% mice remain tumor-
free with long-term survival (p D 0.0001) (Fig. 4D).
T cell responses induced by combining SCIB2 with anti-
CD25 Ab or checkpoint blockade
Results from clinical studies have suggested that Treg depletion
or checkpoint blockade can enhance endogenous T cell
responses and/or recover immune responses within the tumor
environment. Initially, the effect of Treg depletion or checkpoint
blockade on SCIB2 immune responses was assessed. We have
shown that anti-CD25 Ab could effectively eliminate Tregs in
vivo. The percentage of CD4CCD25C FOXP3C cells was reduced
from 0.53% of CD4C cells to 0.00% after administration of anti-
CD25 Ab. However, there was also a depletion of CD4CCD25C
cells from 1.78 to 0.13% suggesting some activated CD4C cells
may also have been depleted. Therefore, prior to the antitumor
studies, it was important to assess the effect of anti-CD25 Ab on
Table 1. NY-ESO-1 incorporated epitopes.
Site Epitope coordinates Epitope sequence HLA HLA frequency (%) References
H1 158–166 LLMWITQCF A24 41 11
H2 157–165 SLLMWITQC A2 44 52-54
H3 83–111 PESRLLEFYLAMPFATPMEAELARRSLAQ
83–91 PESRLLEFY B44 21 Patents WO 2001007917 A1
86–99 RLLEFYLAMPFATP DR2 25 55
88–96 LEFYLAMPF B18 6 56
89–100 EFYLAMPFATPM DR1 18 55
94–102 MPFATPMEA B35/B51 20/12 57,58
92–100 LAMPFATPM Cw3 17 59
87–100 LLEFYLAMPFATPM DR9 3 60
87–111 LLEFYLAMPFATPMEAELARRSLAQ DR1/4/7/DP4 18/24/25/75 12
L1 119–143 PGVLLKEFTVSGNILTIRLTAADHR DR1/4/7 18/24/25 10,25,26,61
123–137 LKEFTVSGNILTIRL DR52b 25 24
124–134 KEFTVSGNILT DR8 4 60
124–135 KEFTVSGNILTI B49 1 62
127–136 TVSGNILTIR A68 8 63
127–135 TVSGNILTI Cw15 3 63
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SCIB2-induced T cell responses. Similar frequencies and avidities
of CD8C epitope-speciﬁc responses were observed with SCIB2 in
the presence or absence of anti-CD25 Ab (Figs. 5A and B). The
cytotoxicity and IFNg release (Fig. 5C and Fig. S2) by SCIB2-
induced T cells was also similar in the presence or absence of
anti-CD25 Ab. This data implies that anti-CD25 Ab had little
effect upon the induction of NY-ESO-1-speciﬁc CD8C responses.
To determine if CTLA-4 or PD-1 blockade could enhance
SCIB2-induced T cell responses, mice were immunized with
SCIB2 in the presence or absence of anti-CTLA-4 or anti-PD-1
Ab. Anti-CTLA-4 and anti-PD-1 Ab did not signiﬁcantly
enhance the frequency (Figs. 6A and D) or avidity (Figs. 6B
and E) of the CD8C T cell responses. However, when spleno-
cytes from SCIB2/anti-CTLA-4-immunized mice were incu-
bated in vitro with NY-ESO-1 157 peptide, they showed
signiﬁcantly enhanced tumor killing of targets expressing NY-
ESO-1 when compared to SCIB2 alone immunized mice
(Fig. 6C). This suggests that anti-CTLA-4 Ab could enhance
CTL cytotoxicity. In contrast, anti-PD-1 Ab did not enhance
the CTL cytotoxicity killing over tumor targets (Fig. 6F).
Figure 2. Epitope-speciﬁc responses generated in HHDII and HHDII/DR1 mice immunized with SCIB2. Splenocytes from SCIB2-immunized HHDII mice (A) and HHDII/DR1
mice (B) were analyzed by IFNg Elispot to show the frequency of responses to NY-ESO-1 157–165, 87–111 and 119–143. Graph shows pooled data from >3 experiments
in which n D 3. (C) Splenocytes from immunized HHDII and HHDII/DR1 mice were assayed for avidity to NY-ESO-1 157–165 peptide by measuring responses to increasing
concentration of peptides in IFNg Elispot assay. (D) After 6 d in vitro stimulation, cytotoxicity of NY-ESO-1 157–165-speciﬁc T cells on tumor lines were assessed by 51Cr-
release assay at a 50:1 effector: target ratio. (E) Granzyme B release from splenocytes of HHDII mice immunized with SCIB2. p < 0.0001, p < 0.001, p < 0.01,
p < 0.05. Data show mean and SD and are representative of at least two experiments where n  3.
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Figure 3. Immune responses and cytotoxicity induced in HHDII mice immunized with SCIB2 or NY-ESO-1 peptides. Comparison of (A) frequency and (B) normalized avid-
ity responses to NY-ESO-1 157–165 peptide measured in IFNg Elispot assay from mice immunized with either SCIB2 or peptide. (C) Cytotoxicity of splenocytes assessed
by 51Cr-release assay. Data are shown at effector to target ratio of 50:1. p < 0.01. Data are presented as mean and SD and are representative of at least two experi-
ments in which n  3.
Figure 4. SCIB2 stimulates strong antitumor immunity. Individual (A and B) and average (C) tumor growth curves and percentage survival (D) of HHD II mice chal-
lenged with 2.5 £ 104 B16/HHDII/NY-ESO-1 tumor cells at day 0 and immunized with SCIB2 at days 4, 11 and 18. p < 0.05. Lack of survival was deﬁned as tumor
size > 528 mm3. (A) and (B) are representative of data from one study in which n D 10. (C) and (D) are representative of data from at least two independent studies
in which n D 10 each study.
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Anti-CD25 Ab and checkpoint blockade enhance the
antitumor effect of SCIB2
As addition of anti-CD25 Ab or checkpoint blockade did not
enhance the SCIB2 vaccine-induced T cell responses, we
assessed if these treatments could enhance tumor rejection. In
order to ensure that the vaccine-induced T cells entering the
tumor were protected from Treg depletion/blocking or check-
point inhibitors, administration of anti-CD25 Ab was initiated
at the same time as tumor challenge and the checkpoint block-
ade antibodies were given at the same time as vaccination.
The combination of anti-CD25 Ab and vaccination with
SCIB2 was assessed in a therapeutic antitumor model (HHDII
mice challenged with 2.5 £ 104 B16/HHDII/NY-ESO-1
tumor cells). Administration of anti-CD25 Ab at the same
time as tumor challenge was not sufﬁcient for tumor rejection
(p > 0.05) (Fig. 7A). However, mice immunized with SCIB2
demonstrate enhanced survival compared to control (p D
0.001) (Fig. 7A). While the combination of anti-CD25 Ab
and SCIB2 vaccination resulted in further inhibition of tumor
growth compared to vaccination with SCIB2 (p D 0.0484)
with 56% of mice showing long-term tumor-free survival
(Fig. 7A).
To further assess the efﬁcacy of combined vaccines, HHDII
mice were given a higher tumor load of B16/HHDII/NY-ESO-1
tumor cells (1.5 £ 105) than in the previous experiment. SCIB2
alone and anti-CD25 Ab alone failed to show any therapeutic
advantage compared to control (Fig. 7B) against these high
tumor load. However, SCIB2 showed synergy with anti-CD25
Ab with 50% long-term survival (Fig. 7B). The combination
group showed a signiﬁcantly higher survival rate than the single
therapies (SCIB2 vs. SCIB2 plus anti-CD25 Ab, p D 0.03; and
anti-CD25 vs. SCIB2 plus anti-CD25, p D 0.04).
The combination of anti-CTLA-4 Ab and vaccination with
SCIB2 was assessed in the therapeutic antitumor model. In
the lower dose model (2.5 £ 104 cells), anti-CTLA-4 Ab and
SCIB2 alone signiﬁcantly delayed tumor growth with long-
term survival of more than 50% (Fig. 7C). This was further
enhanced to 65% improvement of survival when these modali-
ties were combined (Fig. 7C). Using a higher tumor cell dose
(1 £ 105 cells), both single therapy groups still showed a sig-
niﬁcant survival advantage over control (Fig. 7D). However,
the combination therapy induced antitumor responses in 67%
mice which is signiﬁcantly enhanced when compared to single
therapies (control vs. SCIB2, p D 0.021; SCIB2 vs.
SCIB2Canti-CTLA-4 Ab, p D 0.02; anti-CTLA-4 Ab vs.
SCIB2 C anti-CTLA-4 Ab, p D 0.05; control vs. SCIB2Canti-
CTLA-4 Ab, p < 0.0001) (Fig. 7D).
The antitumor effect of combination of PD-1-blocking anti-
body and vaccination with SCIB2 was then assessed. Mice were
challenged with (5 £ 104) B16/HHDII/NY-ESO-1 tumor cells;
anti-PD-1 Ab and SCIB2 alone delayed tumor growth with
long-term survival of 50% (Fig. 7E). This was further enhanced
to 100% improvement of survival when these modalities were
combined (control vs. SCIB2, p D 0.037; control vs. anti-PD-1
Ab, p D 0.11; SCIB2 vs. SCIB2Canti-PD-1 Ab, p D 0.0177;
anti-PD-1 Ab vs. SCIB2 C anti- PD-1 Ab, p D 0.0177; control
vs. SCIB2Canti- PD-1 Ab, p D 0.0003).
Figure 5. T cell responses induced by combining SCIB2 with Treg depletion. (A–C) Mice were immunized with SCIB2 in combination with anti-CD25 Ab. Splenocytes from
immunized mice were assayed at day 20 for (A) frequency of immune responses against 10 mg/mL of NY-ESO-1 157–165 peptide. Graph shows pooled data from >3
experiments in which n D 3. (B) Normalized avidity by titration of NY-ESO-1 157–165 peptide by IFNg Elispot assay. (C) After 6 d in vitro stimulation with NY-ESO-1 157–
165 peptide, CD8C T cells were assessed by 51Cr-release cytotoxicity assay. Data is shown at an effector to target ratio of 50:1. Data show mean and SD and are representa-
tive of at least two experiments, where n  3.
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Discussion
NY-ESO-1 is a cancer testis antigen that has a restricted normal
expression but is expressed by a wide range of tumors.7-9 It is
very immunogenic and many patients have endogenous
responses to this antigen11,12,24,52 as we conﬁrmed in our in
vitro studies from melanoma patients. We showed T cell
response to one or more of 16 T cell epitopes in 82–90% of
patients. Despite the presence of spontaneous T cell responses,
the majority of patients still die of their disease. One of the key
Figure 6. T cell responses induced by combining SCIB2 with checkpoint inhibitors. Mice were immunized with SCIB2 in combination with the anti-CTLA-4 Ab (A–C) or
anti-PD-1 Ab (D–F). (A, D) Frequency of Immune responses against 10 mg/ mL NY-ESO-1 157–165 peptide and (B, E) avidity by titration of NY-ESO-1 157–165 peptide
were measured by IFNg Elispot assay. (C, F) After 6 d in vitro stimulation with NY-ESO-1 157–165 peptide, CD8C T cells were assessed for the ability to kill B16/HHDII/NY-
ESO-I target cells by 51Cr-release cytotoxicity assay. Data are shown at an effector to target ratio of 50:1. p < 0.01. Data are presented as mean and SD. Data are repre-
sentative of at least two experiments in which n  3.
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factors may be failure to generate high-avidity T cells that can
lyse tumor cells. We have previously demonstrated the superi-
ority of the vaccine approach of encoding antigenic epitopes
within a human antibody IgG1 framework for the induction of
high-avidity CD8C and CD4C responses.18,19 SCIB2 was there-
fore designed to encode these 16 NY-ESO-1 epitopes, which
are nested within four regions of NY-ESO-1, in the CDR
regions of the human IgG1 Ab ImmunoBody vector.
Figure 7. Antitumor effect of combination of SCIB2 and Treg depletion and SCIB2 with CTLA-4 or PD-1 blockade. HHDII mice were implanted with B16/HHDII/NY-ESO-1
cells and treated with anti-CD25 Ab, SCIB2 or both. (A) Percentage survival of mice challenged with low-dose (2.5 £ 104) tumor and immunized with SCIB2 and anti-
CD25 Ab alone or in combination. Con vs. SCIB2 (p D 0.001); SCIB2 vs. SCIB2Canti-CD25Ab depletion (p D 0.0484); Con vs. SCIB2Canti-CD25 Ab (p D 0.0006).
(B) Percentage survival rate of mice challenged with high-dose (1.5 £ 105) tumor. Con vs. SCIB2 (p > 0.05); Con vs. anti-CD25 Ab (p > 0.05); SCIB2 vs. SCIB2Canti-
CD25 Ab depletion (p D 0.03); anti-CD25 Ab vs SCIB2Canti-CD25Ab (p D 0.04); (C) Survival of mice challenged with 2.5 £ 104 tumor cells and immunized with
SCIB2 and anti-CTLA-4 Ab alone or in combination. Con vs. anti-CTLA-4 Ab (p D 0.0003); Con vs. SCIB2 (p < 0.0001); anti CTLA-4 Ab vs. anti-CTLA-4 Ab plus
SCIB2 (p > 0.05); SCIB2 vs. SCIB2 plus anti-CTLA-4 Ab (p > 0.05); (D) shows survival of mice challenged with 1 £ 105 tumor cells and immunized with SCIB2 and anti-
CTLA-4 Ab alone or in combination. Con vs. SCIB2 (p D 0.021); SCIB2 vs. SCIB2Canti-CTLA-4 Ab (p D 0.02); anti-CTLA-4 Ab vs. SCIB2 C anti-CTLA-4 Ab (p D 0.05);
Con vs. SCIB2Canti-CTLA-4 Ab (p < 0.0001); (E) Survival of mice challenged with 5 £ 104 tumor cells and immunized with SCIB2 and anti-PD-1 Ab alone or in
combination. Con vs. SCIB2 (p D 0.037); Con vs. anti-PD-1 Ab ( p D 0.111); Con vs. SCIB2Canti-PD-1 Ab (p D 0.0003); SCIB2 vs. SCIB2Canti-PD-1 Ab (p D 0.0177);
anti-PD-1 Ab vs. SCIB2Canti-PD-1 Ab (p D 0.0177). Lack of survival was deﬁned as tumor size > 528 mm3. Each curve represents at least 10 mice per group.
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SCIB2 was tested in HHDII (HLA-A0201) transgenic mice
models. It not only elicited a higher frequency and avidity
response to NY-ESO-1 157 than peptide vaccination but also
generated CD8C responses with the ability to recognize natu-
rally processed and presented NY-ESO-1 antigen on the surface
of tumor cells. This is consistent with our previous ﬁndings that
the frequency and avidity of responses from SCIB1 was signiﬁ-
cantly higher than that from peptide immunization.19 In addi-
tion, SCIB2 induced high-frequency CD4C responses in
HHDII and HHDII/DR1 transgenic mice conﬁrming I-Ab and
demonstrating HLA-DR1 restriction.10,12,25-27 Furthermore, the
induced CD4C cells released granzyme B that could be
completely blocked by MHC class II Ab suggesting that they
were cytotoxic CD4C responses. Recent studies demonstrate
CD4C T cells can possess cytotoxicity abilities and are able to
lyse virus-infected and tumor cells.28,29 NY-ESO-1 87–111-spe-
ciﬁc CD4C CTL lines from cancer patients have also been
shown to recognize autologous APC loaded with protein or
transfected with NY-ESO-1 cDNA.12 MHC II expression can
be induced in majority of cells, including melanoma by IFNg;
it can also be constitutively expressed in some melanomas.30-32
The effect of both CD8C and CD4C responses on tumor ther-
apy was measured using the HHDII transgenic mouse model.
As NY-ESO-1 does not have a murine homolog, the human
NY-ESO-1 was cloned into the B16/HHDII cell line. As a for-
eign antigen, it was anticipated that it may induce an antitumor
response in the absence of vaccination. However, NY-ESO-1-
expressing tumors still grew rapidly in the majority of mice. In
contrast, the strong cytotoxic high-avidity NY-ESO-1-speciﬁc
CD8C and CD4C T cell responses induced by SCIB2 led to
long-term survival in 35% of mice. In this study, we did not
investigate if the antitumor effect induced by SCIB2 was CD4C
and/or CD8C T cells mediated, this will be examined in a future
study. We have shown both CD8C and CD4C responses to NY-
ESO-1 epitopes encoded within SCIB2 DNA constructs could
be generated in patients which gives a good indication that
SCIB2-stimulated responses in humans may involve both
CD8C and CD4C T cells.
Tumors are well known to promote an anti-inﬂammatory
suppressive environment and recent data has demonstrated
that high-avidity CD8C T cells are tolerized within the tumor
environment rendering them non-functional.33 We report that
SCIB2-mediated antitumor responses were further enhanced in
combination with Treg depletion/blocking. Anti-CD25 Ab has
been used in many studies to deplete/block Tregs in murine
models and reports suggest an antitumor role as a monother-
apy or combined with vaccines.34,35 However, its antitumor
efﬁcacy as a monotherapy was limited in aggressive tumor
models, including B16.64 Daclizumab, a human anti-CD25 Ab
has been shown to reduce the presence of Tregs in peripheral
blood; however, its antitumor therapeutic effect has yet to be
determined as it can also eliminate activated T cells.36 A recent
clinical trial demonstrates the synergistic effect of cyclophos-
phamide with multiple peptide vaccines in renal cancer patients
with prolonged survival.37 This effect was not observed in the
absence of immune responses which suggest the importance of
both immune response and immunomodulatory mechanisms.
A vaccination that generates high-avidity T cells could be
used in cancer treatments along with checkpoint inhibitors to
remove the brakes and unleash the full potential of the T cell
response. Indeed, we have shown here that in a preclinical
model, the combination of CTLA-4 with SCIB2 resulted in an
enhanced antitumor response. This is in contrast to other stud-
ies showing that when it is given as monotherapy, anti-CTLA-4
Ab failed to reject tumor in several models (B16, SM1 mam-
mary carcinoma, EL4 lymphoma, M109 lung cancer).38 CTLA-
4 binds to CD80/86 with higher afﬁnity than CD28 and inhibits
the activating signals. Using our immunization regime of co-
vaccinating with the initial and third dose of vaccine, we
showed no increase in the frequency or the avidity of the
SCIB2-induced immune response but did see good additive
antitumor responses. This is in line with other studies showing
that T cell responses can be suppressed within the tumor envi-
ronment and anti-CTLA-4 Ab can reactivate T cells at the
tumor site.39
In our preclinical model, the combination of anti-PD-1 with
SCIB2 resulted in an enhanced antitumor response. Studies in
the B16 tumor model in C57Bl/6 mice have failed to show an
effect with PD-1 blockade alone.40 This may be a reﬂection of
its low immunogenicity and/or the fact it does not normally
express PD-L1 in vivo. Previous studies indicate that the PD-L1
level within the tumor environment can be elevated by inﬁltrat-
ing activated T cells secreting IFNg.41,42 PD-L1 expression
within tumor environment can be related to poor prognosis in
various cancers.43-45 High levels of PD-L1 expression in the
tumor microenvironment have also been correlated with a bet-
ter response rate to PD-1/PD-L1 blockade in cancer patients.46
However, some patients whose tumors do not express PD-L1
also respond to PD-1/PD-L1 blockade. PD-L1 can also be
expressed on inﬁltrating monocytes and endothelial cells and
the role these cells play in checkpoint inhibition remains
unclear. It is suggested that induction of PD-L1 in the mela-
noma tumor microenvironment may suppress T cells mediated
antitumor immune responses by engaging PD-1 on the tumor-
inﬁltrating T cells41 and may also promote iTreg induction,
proliferation and immune suppressive function.48 Recent stud-
ies showed, in addition to blocking negative pathway in
immune cells, the checkpoint inhibitors (anti CTLA-4 and anti
PD-1 Abs) also eliminates Treg.40,49,50 Within the tumor envi-
ronment, depletion of Tregs by anti-CTLA-4 is dependent on
the presence of Fcg receptor-expressing receptor macro-
phage.50 This is consistent with our results in which anti-
CTLA-4 and anti-PD-1 Abs failed to increase the immune
response to SCIB2 but did enhance its antitumor response with
100% of mice showing long-term survival with the SCIB2/anti-
PD-1 combination.
In conclusion, this study shows that targeting NY-ESO-1
epitopes to antigen-presenting cells results in high-avidity and
high-frequency T cell immune responses, with potent antitu-
mor responses, which were further enhanced by checkpoint
blockade. The 100% tumor survival with the combination of
SCIB2 and PD-1 blockade is especially promising as PD-1
blockade is known to have lower associated toxicity when com-
pared to CTLA-4 blockade. SCIB2 will now be rapidly trans-
lated into the clinic where it is anticipated that patients with
low tumor burden may beneﬁt from SCIB2 alone but patients
with more bulky disease may beneﬁt from combinations of
SCIB2 with checkpoint blockade.
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Materials and methods
Vaccine and expression plasmids
In brief, to generate SCIB2 oligonucleotides encoding the HLA-
A24 epitope 158–166 (LLMWITQCF) and HLA-A2-restricted
epitope 157–165 (SLLMWITQC) were incorporated into the
CDRH1 and CDRH2 of the vector pDCOrig, respectively, as
previously described.18 The NY-ESO-1 amino acid sequence
83–111 (PESRLLEFYLAMPFATPMEAELARRSLAQ) was
cloned into the CDRH3 site. NY-ESO-1 amino acid sequence
119–143 (PGVLLKEFTVSGNILTIRLTAADHR) was inserted
into the CDRHL1 site within the light chain.
To construct the mammalian double expression plasmid
that encodes murine TAP2 and NY-ESO-1, NY-ESO-1 was
ampliﬁed from the IMAGE clones 40146393 obtained from
Genservice with forward and reverse primers that incorporated
a BamH1/XhoI site, respectively. On sequence conﬁrmation,
full-length NY-ESO-1 was ligated into the BamHI/Xho1 multi-
ple cloning site of the double expression vector in replacement
of the light chain. Murine TAP2 (after site-directed mutagene-
sis of the image clone 6530488 to remove a HindIII site from
encoding sequence and insertion before the start codon) was
cloned into the expression vector pOrigHIB using HindIII/
EcoRV, then transferred in replacement of the heavy chain
using HindIII/AvrII into the double expression vector along-
side full length NY-ESO-1.
To generate the HHD plasmid, cDNA was synthesized
from total RNA isolated from EL4-HHD cells. This was used
as a template to amplify HHD using the forward and reverse
primers and subcloned into pCR2.1. The HHD chain, com-
prising of a human HLA-A2 leader sequence, the human
b2-microglobulin (b2M) molecule covalently linked via a
glycine serine linker to the a 1 and 2 domains of human
HLA-0201 MHC class 1 molecule and the a3, transmem-
brane and cytoplasmic domains of the murine H-2Db class
1 molecule, was then inserted into the EcoRV/HindIII sites
of the mammalian expression vector pCDNA3.1 obtained
from Invitrogen.
In order to knockdown expression of murine b2M and
murine MHC class II in the cell line B16F10, RNA interference
was utilized. Complimentary oligonucleotides that target
sequence 266 of murine b2M and 159 of murine MHC class II
were annealed and inserted separately into pCDNA6.2 GW
miR (Invitrogen). The pre-miRNA expression cassette contain-
ing miRNA 266 was excised using BamHI/XhoI and ligated
into the XhoI/BglII site of pCDNA6.2 GW miR 159 in order to
chain the two miRNAs and express them in one primary tran-
script within the same vector.
Cell lines
B16F10 cell line (ATCC) was maintained in RPMI (Cambrex)
with 10% FBS (Sigma). B16F10 cells were transfected successively
using Lipofectamine transfection reagent (Invitrogen) with
expression vectors encoding full-length NY-ESO-1 and Murine
TAP2, HHDII and a siRNA to knockdown expression of murine
MHC class II and murine b2M. Transfected cells were selected
by growth in the presence of Zeocin (300 mg/ mL), G418
(500 mg/ mL) and Blasticidin (4 mg/ mL), respectively. Lines
were cloned by limiting dilution and expression was conﬁrmed
by ﬂow cytometry.
Mice and immunizations
Animal work was carried out under a Home Ofﬁce approved
project license at Nottingham Trent University. HLA-A2/DR1
(HHDII/DR1) or HLA-A2 (HHDII) transgenic mice on a
C57Bl/6 background (Pasteur Institute) were used between 6
and 16 weeks of age. HHDII mice are murine class I deﬁcient
and express the human HLA-A2 allele. HHDII/DR1 mice are
deﬁcient in both murine MHC class I and II and replaced
with the human HLA-A2 and DR1 alleles. Synthetic peptide
SLLMWITQC (NY-ESO-1 157–165) was emulsiﬁed with IFA/
CFA combination (Invivogen). Peptide (25 mg/immunization)
was injected via the subcutaneous route at the base of the tail.
DNA was coated onto 1.0 mm gold particles (Bio-Rad) using
the manufacturer’s instructions and administered intrader-
mally by the Helios Gene Gun (Bio-Rad). Each mouse
received 1 mg DNA/immunization into the shaved abdomen.
Depletion of Tregs was performed by intraperitoneal injection
of 400 mg anti-CD25 Ab (PC61) (BioXcell) 4 d prior to the
ﬁrst immunization. Mice were immunized at day 1, 8 and 15
and spleens removed at day 20 for analysis, unless otherwise
stated. The half-life of the hamster anti-CTLA-4 (9H10) Ab in
vivo has been shown to be 3–4 d.51 The rat anti PD-1 (RPM1-
14) Ab has a slightly longer half-life and is usually adminis-
tered every 4–7 d. For consistency, we gave both checkpoint
blockade antibodies weekly with the ﬁrst and last SCIB2
administration. Anti-CTLA-4 Ab (9H10) or anti-PD-1 Ab
(RMP1-14) (BioXcell) was injected at 200 or 250 mg intraperi-
toneally at day 1 and 15.
Proliferation assay
PBMC from melanoma patients were isolated by Ficol-Hypa-
que (Sigma) gradient centrifugation. In brief, PBMC (1.5 £
106cell/well) were stimulated with peptide (10 mg/ mL) for 10 d
at 37C. The cultured PBMC were then incubated with 3H-thy-
midine (0.0185 MBq/well) for 8 h at 37C. The cultures were
harvested onto uniﬁlter plates and incorporation of 3H-thymi-
dine was determined by b-scintillation counting. The results
were assessed by calculating the proliferation index (PI) as the
ratio of the mean of counts per minutes (cpm) of epitope-stim-
ulated to the mean of unstimulated cultures. The proliferative
assay was considered positive when PI > 2.5.
Ex vivo Elispot assay
Elispot assays were performed using murine IFNg capture and
detection reagents according to the manufacturer’s instructions
(Mabtech AB). Detailed method was described previously.19
Synthetic peptides SLLMWITQC (NY-ESO-1 157–165), LLE-
FYLAMPFATPMEAELARRSLAQ (NY-ESO-1 87–111) and
PGVLLKEFTVSGNILTIRLTAADHR (NY-ESO-1 119–143) (at
a variety of concentrations) were used in these assays. Anti-
mouse MHC-II IAb blocking Ab (M5/114.15.2) was purchased
from ebioscience. Anti HLA-DR blocking Ab (L243) was
obtained from Biolegend.
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Re-stimulation in vitro
Splenocytes (5 £ 106/ mL) were co-cultured at 37C with irra-
diated, peptide-pulsed LPS blast. LPS blasts were obtained by
activating splenocytes (1.5 £ 106/ mL) with 25 mg/ mL LPS
(Sigma) and 7 mg/ mL dextran sulfate (Pharmacia) for 48 h at
37C. Before use, 2 £ 107 LPS blasts were labeled with 10 mg/
mL synthetic peptide for 1 h. Anti CTLA-4 Ab and PD-1 Ab
were used at 40 mg/mL. After six days, cultures were assays for
cytotoxic activity in a 51Cr-release assay.
CTL assay
Target cells were labeled for 90 min with 1.85 MBq sodium
(51Cr) chromate (Amersham) in the presence or absence of
1 mg/mL (NY-ESO-1 157) peptides. Targets cells (5 £ 103/
well) were then incubated with different numbers of effector
cells in a ﬁnal volume of 200 mL. After 4 h incubation at 37C,
50 mL of supernatants were transferred to a Lumaplate (Perkin
Elmer). Plates were then read on a Topcount Microplate Scin-
tillation Counter (Packard). Percentage-speciﬁc lysis was calcu-
lated using the following formula: speciﬁc lysis D 100 £
[(experimental release minus spontaneous release)/(maximum
release minus spontaneous release)].
Granzyme B ELISA
Supernatant from ex vivo IFNg Elispot assays was analyzed
using a granzyme B Elisa kit according to manufacturer’s
instruction (R&D system).
Tumor studies
In the therapeutic model, HLA-A2 transgenic (HHDII) mice
were challenged by subcutaneous injection with 2.5 £ 104 B16/
HHDII/NY-ESO-1 cells at day 1. Anti-CD25 Ab (400 mg/
mouse) was injected intraperitoneally concurrent with tumor
cell implant on day 1. The vaccination groups were immunized
with DNA bullets intradermally using the Helios Gene Gun for
three consecutive weeks at day 4, 11 and 18. For a more aggres-
sive tumor model, 1.5 £ 105 B16/HHDII/NY-ESO-1 cells was
injected on day 1. For checkpoint blockade tumor model, the
vaccine groups were immunized with DNA bullets at day 4, 7
and 11. Anti-CTLA-4 Ab (200 mg/mouse; BioXcell) or anti-
PD-1 (250 mg/mouse, BioXcell) was injected intraperitoneally
on day 4 and 11. The end point for tumor therapy studies was
when tumor exceeded 528 mm3.
Statistical analysis
Comparative analysis of the Elispot, Elisa, CTL killing assay
and tumor size results was performed by applying the student’s
t test with values of p calculated accordingly. Paired Wilcoxon
ranking test was used to compare peptide with media Elispot
responses from the same mice. Comparison of avidity curves
and tumor growth was performed by applying the two-way
ANOVA and survival studies were assessed by Log Rank test
using the Graphpad Prism 5.0 software (GraphPad Software,
Inc.). p < 0.05 was considered statistically signiﬁcant.
Disclosure of potential conﬂicts of interest
The authors wish to disclose that Lindy G. Durrant is a director of Scancell
Ltd and W. X., R. L. M., V. A. B., P. S., and B. G. are employees of Scancell
Ltd.
Acknowledgments
The authors would like to thank Dr Ian Daniels and Dr Katherine Cook for
their help in proofreading the manuscript. The authors wish to thank H.
Yagita for permission to use anti-PD-1 Ab.
Funding
This work was funded by Scancell Ltd.
References
1. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen
JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al. Improved
survival with ipilimumab in patients with metastatic melanoma. N
Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/
10.1056/NEJMoa1003466
2. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDer-
mott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB et al.
Safety, activity, and immune correlates of anti-PD-1 antibody in can-
cer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.
org/10.1056/NEJMoa1200690
3. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD,
Schadendorf D, Dummer R, Smylie M, Rutkowski P et al. Combined
nivolumab and ipilimumab or monotherapy in untreated melanoma.
N Engl J Med 2015; 373:23-34; PMID:26027431; http://dx.doi.org/
10.1056/NEJMoa1504030
4. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard
A, Walsh LA, Postow MA, Wong P, Ho TS et al. Genetic basis for
clinical response to CTLA-4 blockade in melanoma. N Engl J Med
2014; 371:2189-99; PMID:25409260; http://dx.doi.org/10.1056/
NEJMoa1406498
5. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Iva-
nova Y, Hundal J, Arthur CD, Krebber WJ et al. Checkpoint blockade
cancer immunotherapy targets tumour-speciﬁc mutant antigens.
Nature 2014; 515:577-81; PMID:25428507; http://dx.doi.org/10.1038/
nature13988
6. Brentville VA, Metheringham RL, Gunn B, Durrant LG. High avidity
cytotoxic T lymphocytes can be selected into the memory pool but
they are exquisitely sensitive to functional impairment. PloS One
2012; 7:e41112; PMID:22829916; http://dx.doi.org/10.1371/journal.
pone.0041112
7. Lee L, Wang RF, Wang X, Mixon A, Johnson BE, Rosenberg SA,
Schrump DS. NY-ESO-1 may be a potential target for lung cancer
immunotherapy. Cancer J Sci Am 1999; 5:20-5; PMID:10188057
8. Akcakanat A, Kanda T, Tanabe T, Komukai S, Yajima K, Nakagawa S,
Ohashi M, Hatakeyama K. Heterogeneous expression of GAGE, NY-
ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications
for immunotherapy. Int J Cancer 2006; 118:123-8; PMID:16003736;
http://dx.doi.org/10.1002/ijc.21219
9. Nicholaou T, Ebert L, Davis ID, Robson N, Klein O, Maraskovsky E,
Chen W, Cebon J. Directions in the immune targeting of cancer: les-
sons learned from the cancer-testis Ag NY-ESO-1. Immunol Cell Biol
2006; 84:303-17; PMID:16681828; http://dx.doi.org/10.1111/j.1440-
1711.2006.01446.x
10. Zarour HM, Maillere B, Brusic V, Coval K, Williams E, Pouvelle-Mor-
atille S, Castelli F, Land S, Bennouna J, Logan T et al. NY-ESO-1 119-
143 is a promiscuous major histocompatibility complex class II T-
helper epitope recognized by Th1- and Th2-type tumor-reactive
CD4C T cells. Cancer Res 2002; 62:213-8; PMID:11782380
11. Yamaguchi H, Tanaka F, Ohta M, Inoue H, Mori M. Identiﬁcation of
HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-
ONCOIMMUNOLOGY e1169353-11
ESO-1, and induction of a speciﬁc antitumor immune response. Clin
Cancer Res 2004; 10:890-6; PMID:14871964; http://dx.doi.org/
10.1158/1078-0432.CCR-1086-3
12. Mandic M, Castelli F, Janjic B, Almunia C, Andrade P, Gillet D, Brusic
V, Kirkwood JM, Maillere B, Zarour HM. One NY-ESO-1-derived
epitope that promiscuously binds to multiple HLA-DR and HLA-DP4
molecules and stimulates autologous CD4C T cells from patients with
NY-ESO-1-expressing melanoma. J Immunol 2005; 174:1751-9;
PMID:15661941; http://dx.doi.org/10.4049/jimmunol.174.3.1751
13. Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann
A, Rieckenberg J, Chen YT, Ritter G et al. Induction of primary NY-
ESO-1 immunity: CD8C T lymphocyte and antibody responses in
peptide-vaccinated patients with NY-ESO-1C cancers. Proc Natl
Acad Sci USA 2000; 97:12198-203; PMID:11027314; http://dx.doi.org/
10.1073/pnas.220413497
14. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley
ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL et al. Tumor
regression in patients with metastatic synovial cell sarcoma and mela-
noma using genetically engineered lymphocytes reactive with NY-
ESO-1. J Clin Oncol 2011; 29:917-24; PMID:21282551; http://dx.doi.
org/10.1200/JCO.2010.32.2537
15. Jager E, Karbach J, Gnjatic S, Neumann A, Bender A, Valmori D,
Ayyoub M, Ritter E, Ritter G, Jager D et al. Recombinant vaccinia/
fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-
ESO-1-speciﬁc immune responses in cancer patients. Proc Natl Acad
Sci USA 2006; 103:14453-8; PMID:16984998; http://dx.doi.org/
10.1073/pnas.0606512103
16. Bender A, Karbach J, Neumann A, Jager D, Al-Batran SE, Atmaca A,
Weidmann E, Biskamp M, Gnjatic S, Pan L et al. LUD 00-009: phase
1 study of intensive course immunization with NY-ESO-1 peptides in
HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer
Immun 2007; 7:16; PMID:17944437
17. Chen Q, Jackson H, Shackleton M, Parente P, Hopkins W, Sturrock S,
MacGregor D, Maraskovsky E, Tai TY, Dimopoulos N et al. Charac-
terization of antigen-speciﬁc CD8C T lymphocyte responses in skin
and peripheral blood following intradermal peptide vaccination. Can-
cer Immun 2005; 5:5; PMID:15755075
18. Metheringham RL, Pudney VA, Gunn B, Towey M, Spendlove I, Dur-
rant LG. Antibodies designed as effective cancer vaccines. mAbs 2009;
1:71-85; PMID:20046577; http://dx.doi.org/10.4161/mabs.1.1.7492
19. Pudney VA, Metheringham RL, Gunn B, Spendlove I, Ramage JM,
Durrant LG. DNA vaccination with T-cell epitopes encoded within
Ab molecules induces high-avidity anti-tumor CD8C T cells. Eur J
Immunol 2010; 40:899-910; PMID:20039301; http://dx.doi.org/
10.1002/eji.200939857
20. Chiarella P, Massi E, De Robertis M, Sibilio A, Parrella P, Fazio VM,
Signori E. Electroporation of skeletal muscle induces danger signal
release and antigen-presenting cell recruitment independently of
DNA vaccine administration. Expert Opin Biol Ther 2008; 8:1645-57;
PMID:18847301; http://dx.doi.org/10.1517/14712598.8.11.1645
21. van Drunen Littel-van den Hurk S, Hannaman D. Electroporation for
DNA immunization: clinical application. Expert Rev Vaccines 2010;
9:503-17; PMID:20450325; http://dx.doi.org/10.1586/erv.10.42
22. Poulam M, Patel CO CM, Lorigan P, Plummer R, Hannaman D, Cun-
nell M, Metheringham R, Brentville V, Daniel I, Machado L et al. An
adjuvant clinical trial of SCIB1, a DNA vaccine that targets dendritic
cells in vivo, in fully resected melanoma patients. ASCO Annual Meet
2015
23. Jager E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J, Dunbar
PR, Lee SY, Jungbluth A, Jager D et al. Monitoring CD8 T cell
responses to NY-ESO-1: correlation of humoral and cellular immune
responses. Proc Natl Acad Sci USA 2000; 97:4760-5; PMID:10781081;
http://dx.doi.org/10.1073/pnas.97.9.4760
24. Bioley G, Dousset C, Yeh A, Dupont B, Bhardwaj N, Mears G, Old LJ,
Ayyoub M, Valmori D. Vaccination with recombinant NY-ESO-1
protein elicits immunodominant HLA-DR52b-restricted CD4C T cell
responses with a conserved T cell receptor repertoire. Clin Cancer Res
2009; 15:4467-74; PMID:19531622; http://dx.doi.org/10.1158/1078-
0432.CCR-09-0582
25. Zarour HM, Storkus WJ, Brusic V, Williams E, Kirkwood JM. NY-
ESO-1 encodes DRB10401-restricted epitopes recognized by mela-
noma-reactive CD4C T cells. Cancer Res 2000; 60:4946-52;
PMID:10987311
26. Ayyoub M, Pignon P, Dojcinovic D, Raimbaud I, Old LJ, Luescher I,
Valmori D. Assessment of vaccine-induced CD4 T cell responses to
the 119-143 immunodominant region of the tumor-speciﬁc antigen
NY-ESO-1 using DRB10101 tetramers. Clin Cancer Res 2010;
16:4607-15; PMID:20670945; http://dx.doi.org/10.1158/1078-0432.
CCR-10-1485
27. Lopes L, Dewannieux M, Gileadi U, Bailey R, Ikeda Y, Whittaker C,
Collin MP, Cerundolo V, Tomihari M, Ariizumi K et al. Immuniza-
tion with a lentivector that targets tumor antigen expression to den-
dritic cells induces potent CD8C and CD4C T-cell responses. J Virol
2008; 82:86-95; PMID:17959670; http://dx.doi.org/10.1128/
JVI.01289-07
28. MacArthur GJ, Wilson AD, Birchall MA, Morgan AJ. Primary CD4C
T-cell responses provide both helper and cytotoxic functions during
Epstein-Barr virus infection and transformation of fetal cord blood B
cells. J Virol 2007; 81:4766-75; PMID:17314172; http://dx.doi.org/
10.1128/JVI.02608-06
29. Perez-Diez A, Joncker NT, Choi K, Chan WF, Anderson CC, Lantz O,
Matzinger P. CD4 cells can be more efﬁcient at tumor rejection than
CD8 cells. Blood 2007; 109:5346-54; PMID:17327412; http://dx.doi.
org/10.1182/blood-2006-10-051318
30. Deffrennes V, Vedrenne J, Stolzenberg MC, Piskurich J, Barbieri G,
Ting JP, Charron D, Alcaide-Loridan C. Constitutive expression of
MHC class II genes in melanoma cell lines results from the transcrip-
tion of class II transactivator abnormally initiated from its B cell-spe-
ciﬁc promoter. J Immunol 2001; 167:98-106; PMID:11418637; http://
dx.doi.org/10.4049/jimmunol.167.1.98
31. Mach B, Steimle V, Martinez-Soria E, Reith W. Regulation of MHC
class II genes: lessons from a disease. Ann Rev Immunol 1996; 14:301-
31; PMID:8717517; http://dx.doi.org/10.1146/annurev.immunol.14.1.301
32. Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B.
Regulation of MHC class II expression by interferon-gamma mediated
by the transactivator gene CIITA. Science 1994; 265:106-9;
PMID:8016643; http://dx.doi.org/10.1126/science.8016643
33. Zhu Z, Singh V, Watkins SK, Bronte V, Shoe JL, Feigenbaum L, Hur-
witz AA. High-avidity T cells are preferentially tolerized in the tumor
microenvironment. Cancer Res 2013; 73:595-604; PMID:23204239;
http://dx.doi.org/10.1158/0008-5472.CAN-12-1123
34. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E.
Tumor rejection by in vivo administration of anti-CD25 (interleukin-
2 receptor alpha) monoclonal antibody. Cancer Res 1999; 59:3128-33;
PMID:10397255
35. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN,
Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ. Synergism
of cytotoxic T lymphocyte-associated antigen 4 blockade and deple-
tion of CD25(C) regulatory T cells in antitumor therapy reveals alter-
native pathways for suppression of autoreactive cytotoxic T
lymphocyte responses. J Exp Med 2001; 194:823-32; PMID:11560997;
http://dx.doi.org/10.1084/jem.194.6.823
36. Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody dacli-
zumab to enhance immune responses to tumor antigen vaccination
by targeting regulatory T cells. Ann N Y Acad Sci 2009; 1174:99-106;
PMID:19769742; http://dx.doi.org/10.1111/j.1749-6632.2009.04939.x
37. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik
C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R et al. Multipeptide
immune response to cancer vaccine IMA901 after single-dose cyclo-
phosphamide associates with longer patient survival. Nat Med 2012;
18:1254-61; PMID:22842478; http://dx.doi.org/10.1038/nm.2883
38. Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an
overview of preclinical and translational research. Cancer Immun
2013; 13:5; PMID:23390376
39. Shrikant P, Khoruts A, Mescher MF. CTLA-4 blockade reverses
CD8C T cell tolerance to tumor by a CD4C T cell- and IL-2-depen-
dent mechanism. Immunity 1999; 11:483-93; PMID:10549630; http://
dx.doi.org/10.1016/S1074-7613(00)80123-5
e1169353-12 W. XUE ET AL.
40. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4
combination blockade expands inﬁltrating T cells and reduces regula-
tory T and myeloid cells within B16 melanoma tumors. Proc Natl
Acad Sci USA 2010; 107:4275-80; PMID:20160101; http://dx.doi.org/
10.1073/pnas.0915174107
41. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajew-
ski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma
tumor microenvironment is driven by CD8(C) T cells. Sci Transl
Med 2013; 5:200ra116; PMID:23986400; http://dx.doi.org/10.1126/
scitranslmed.3006504
42. Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R,
Yamaguchi K, Yoshioka Y, Baba T, Konishi I, Mandai M. IFN-gamma
from lymphocytes induces PD-L1 expression and promotes progres-
sion of ovarian cancer. Br J Cancer 2015; 112:1501-9;
PMID:25867264; http://dx.doi.org/10.1038/bjc.2015.101
43. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Web-
ster WS, Sengupta S, Frank I, Parker AS, Zincke H et al. Tumor B7-
H1 is associated with poor prognosis in renal cell carcinoma patients
with long-term follow-up. Cancer Res 2006; 66:3381-5;
PMID:16585157; http://dx.doi.org/10.1158/0008-5472.CAN-05-4303
44. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, Oka-
zaki T, Tokura Y. Tumor cell expression of programmed cell death-1
ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010;
116:1757-66; PMID:20143437; http://dx.doi.org/10.1002/cncr.24899
45. Dolan DE, Gupta S. PD-1 pathway inhibitors: changing the landscape
of cancer immunotherapy. Cancer Control 2014; 21:231-7;
PMID:24955707
46. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS,
Sosman JA, McDermott DF, Powderly JD, Gettinger SN et al. Predic-
tive correlates of response to the anti-PD-L1 antibody MPDL3280A in
cancer patients. Nature 2014; 515:563-7; PMID:25428504; http://dx.
doi.org/10.1038/nature14011
47. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel
JC, Rutkowski P, McNeil C, Kalinka-Warzocha E et al. Nivolumab in
previously untreated melanoma without BRAF mutation. N Engl J
Med 2015; 372:320-30; PMID:25399552; http://dx.doi.org/10.1056/
NEJMoa1412082
48. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuch-
roo VK, Sharpe AH. PD-L1 regulates the development, maintenance,
and function of induced regulatory T cells. J Exp Med 2009; 206:3015-
29; PMID:20008522; http://dx.doi.org/10.1084/jem.20090847
49. Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J. PD1 blockade
reverses the suppression of melanoma antigen-speciﬁc CTL by CD4C
CD25(Hi) regulatory T cells. Int Immunol 2009; 21:1065-77;
PMID:19651643; http://dx.doi.org/10.1093/intimm/dxp072
50. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K,
Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD et al. Fc-dependent
depletion of tumor-inﬁltrating regulatory T cells co-deﬁnes the efﬁcacy
of anti-CTLA-4 therapy against melanoma. J Exp Med 2013; 210:1695-
710; PMID:23897981; http://dx.doi.org/10.1084/jem.20130579
51. Rohlman D, Punj S, Pennington J, Bradford S, Kerkvliet NI. Suppres-
sion of acute graft-versus-host response by TCDD is independent of
the CTLA-4-IFN-gamma-IDO pathway. Toxicol Sci 2013; 135:81-90;
PMID:23798565; http://dx.doi.org/10.1093/toxsci/kft140
52. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D,
Arand M, Wada H, Noguchi Y, Stockert E et al. Simultaneous
humoral and cellular immune response against cancer-testis antigen
NY-ESO-1: deﬁnition of human histocompatibility leukocyte antigen
(HLA)-A2-binding peptide epitopes. J Exp Med 1998; 187:265-70;
PMID:9432985; http://dx.doi.org/10.1084/jem.187.2.265
53. Chen JL, Dunbar PR, Gileadi U, Jager E, Gnjatic S, Nagata Y, Stockert
E, Panicali DL, Chen YT, Knuth A et al. Identiﬁcation of NY-ESO-1
peptide analogues capable of improved stimulation of tumor-reactive
CTL. J Immunol 2000; 165:948-55; PMID:10878370; http://dx.doi.
org/10.4049/jimmunol.165.2.948
54. Valmori D, Dutoit V, Lienard D, Rimoldi D, Pittet MJ, Champagne P,
Ellefsen K, Sahin U, Speiser D, Lejeune F et al. Naturally occurring
human lymphocyte antigen-A2 restricted CD8C T-cell response to
the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer
research 2000; 60:4499-506; PMID:10969798
55. Chen Q, Jackson H, Parente P, Luke T, Rizkalla M, Tai TY, Zhu HC,
Mifsud NA, Dimopoulos N, Masterman KA et al. Immunodominant
CD4C responses identiﬁed in a patient vaccinated with full-length
NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad
Sci USA 2004; 101:9363-8; PMID:15197261; http://dx.doi.org/
10.1073/pnas.0403271101
56. Zhao RY, Mifsud NA, Xiao K, Chan KF, Oveissi S, Jackson HM,
Dimopoulos N, Guillaume P, Knights AJ, Lowen T et al. A novel
HLA-B18 restricted CD8C T cell epitope is efﬁciently cross-pre-
sented by dendritic cells from soluble tumor antigen. PloS One
2012; 7:e44707; PMID:22970293; http://dx.doi.org/10.1371/journal.
pone.0044707
57. Benlalam H, Linard B, Guilloux Y, Moreau-Aubry A, Derre L, Diez E,
Dreno B, Jotereau F, Labarriere N. Identiﬁcation of ﬁve new HLA-
B3501-restricted epitopes derived from common melanoma-associ-
ated antigens, spontaneously recognized by tumor-inﬁltrating lym-
phocytes. J Immunol 2003; 171:6283-9; PMID:14634146; http://dx.
doi.org/10.4049/jimmunol.171.11.6283
58. Jager E, Karbach J, Gnjatic S, Jager D, Maeurer M, Atmaca A, Arand
M, Skipper J, Stockert E, Chen YT et al. Identiﬁcation of a naturally
processed NY-ESO-1 peptide recognized by CD8C T cells in the con-
text of HLA-B51. Cancer Immun 2002; 2:12; PMID:12747757
59. Gnjatic S, Nagata Y, Jager E, Stockert E, Shankara S, Roberts BL, Maz-
zara GP, Lee SY, Dunbar PR, Dupont B et al. Strategy for monitoring
T cell responses to NY-ESO-1 in patients with any HLA class I allele.
Proc Natl Acad Sci USA 2000; 97:10917-22; PMID:11005863; http://
dx.doi.org/10.1073/pnas.97.20.10917
60. Mizote Y, Taniguchi T, Tanaka K, Isobe M, Wada H, Saika T, Kita S,
Koide Y, Uenaka A, Nakayama E. Three novel NY-ESO-1 epitopes
bound to DRB10803, DQB10401 and DRB10901 recognized by
CD4 T cells from CHP-NY-ESO-1-vaccinated patients. Vaccine 2010;
28(32):5338-5346; PMID:20665979; http://dx.doi.org/10.1016/j.
vaccine.2010.05.044
61. Jager E, Jager D, Karbach J, Chen YT, Ritter G, Nagata Y, Gnjatic S,
Stockert E, Arand M, Old LJ et al. Identiﬁcation of NY-ESO-1 epitopes
presented by human histocompatibility antigen (HLA)-DRB40101-
0103 and recognized by CD4(C) T lymphocytes of patients with NY-
ESO-1-expressing melanoma. J Exp Med 2000; 191:625-30;
PMID:10684854; http://dx.doi.org/10.1084/jem.191.4.625
62. Knights AJ, Nuber N, Thomson CW, de la Rosa O, Jager E, Tiercy JM,
van den Broek M, Pascolo S, Knuth A, Zippelius A. Modiﬁed tumour
antigen-encoding mRNA facilitates the analysis of naturally occurring
and vaccine-induced CD4 and CD8 T cells in cancer patients. Cancer
Immunol Immunother 2009; 58:325-38; PMID:18663444; http://dx.
doi.org/10.1007/s00262-008-0556-8
63. Matsuzaki J, Qian F, Luescher I, Lele S, Ritter G, Shrikant PA, Gnjatic
S, Old LJ, Odunsi K. Recognition of naturally processed and ovarian
cancer reactive CD8C T cell epitopes within a promiscuous HLA class
II T-helper region of NY-ESO-1. Cancer Immunol Immunother 2008;
57:1185-95; PMID:18253733; http://dx.doi.org/10.1007/s00262-008-
0450-4
64. Nagai H, Horikawa T, Hara I, Fukunaga A, Oniki S, Oka M, Nishigori
C and Ichihashi M. In vivo elimination of CD25C regulatory T cells
leads to tumor rejection of B16F10 melanoma, when combined with
interleukin-12 gene transfer. Experimental dermatology. 2004; 13
(10):613-620; PMID:15447721
ONCOIMMUNOLOGY e1169353-13
